Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETVAX phase 1 safety and immunogenicity study in healthy adults, children, and infants in Zambia
PACTR201905764389804Phase 1Completed
- Sponsor
- Scandinavian Biopharma
- Start
- Jun 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1 trial of ETVAX in Enterotoxigenic Escherichia coli diarrhea (7 cohorts), sponsored by Scandinavian Biopharma. Primary endpoints: Solicited gastrointestinal reactions, Solicited systemic reactions and 3 more. Started Jun 2019; status: completed.
02
Drugs
ETVAX
03
Conditions
Enterotoxigenic Escherichia coli diarrhea
Beyond the preview
Go deeper on PACTR201905764389804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201905764389804.